Scarica l'app Stockscreener
2.55
2.00%
0.05
Dopo l'orario di chiusura:
2.55
Precedente Chiudi:
$2.50
Aprire:
$2.45
Volume 24 ore:
30,742
Relative Volume:
0.46
Capitalizzazione di mercato:
$10.81M
Reddito:
-
Utile/perdita netta:
$-21.79M
Rapporto P/E:
-0.4124
EPS:
-6.1838
Flusso di cassa netto:
$-23.12M
1 W Prestazione:
-12.07%
1M Prestazione:
-14.72%
6M Prestazione:
-56.03%
1 anno Prestazione:
+744.09%
Intervallo 1D:
$2.44
$2.625
Intervallo di 1 settimana:
$2.43
$2.87
Portata 52W:
$0.23
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Nome
Cellectar Biosciences Inc
Settore
Industria
Telefono
(608) 441-8120
Indirizzo
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
2.55 | 10.81M | 0 | -21.79M | -23.12M | -6.1838 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Aggiornamento | Maxim Group | Hold → Buy |
| 2024-12-05 | Ripresa | Ladenburg Thalmann | Buy |
| 2020-07-01 | Iniziato | Oppenheimer | Outperform |
| 2020-01-21 | Ripresa | ROTH Capital | Buy |
| 2019-09-13 | Iniziato | ROTH Capital | Buy |
| 2016-12-21 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Cellectar Biosciences Inc Borsa (CLRB) Ultime notizie
Earnings call transcript: Cellectar Biosciences Q4 2025 reveals strategic cost control - Investing.com
Aug Technicals: Will Cellectar Biosciences Inc outperform during market ralliesOil Prices & Risk Managed Investment Strategies - baoquankhu1.vn
Smart Money: Is Cellectar Biosciences Inc a top pick in the sectorQuarterly Trade Summary & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
VIX Spike: Can Cellectar Biosciences Inc weather a recessionTrade Risk Assessment & Community Verified Trade Alerts - baoquankhu1.vn
What drives Cellectar Biosciences Incs stock price2026 Risk Factors & Weekly High Potential Stock Alerts - baoquankhu1.vn
ETF Watch: Will WASH benefit from geopolitical trendsShare Buyback & Stepwise Trade Signal Implementation - baoquankhu1.vn
Big Money Moves: How cyclical is Cellectar Biosciences Incs revenue streamTrade Entry Report & Smart Swing Trading Alerts - baoquankhu1.vn
If You Invested $1,000 in Cellectar Biosciences Inc (CLRB) - Stock Titan
Meme Stocks: Can Cellectar Biosciences Inc disrupt its industryMarket Trend Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Aug Patterns: How does Cellectar Biosciences Inc compare to its peers2026 Volume Leaders & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Layoff Watch: Will Cellectar Biosciences Inc stock benefit from M A2026 Earnings Impact & Fast Moving Market Watchlists - baoquankhu1.vn
Trading Recap: Can Cellectar Biosciences Inc weather a recessionWeekly Investment Report & Safe Capital Investment Plans - baoquankhu1.vn
Risk Report: Does Cellectar Biosciences Inc have a sustainable dividendTake Profit & Daily Stock Trend Watchlist - baoquankhu1.vn
Rate Cut: Can Cellectar Biosciences Inc weather a recessionMarket Growth Report & Short-Term Trading Alerts - baoquankhu1.vn
Cellectar Biosciences (NASDAQ:CLRB) Rating Increased to Buy at Maxim Group - Defense World
CLRB: Maxim Group Upgrades Cellectar Biosciences to Buy with $10 Target | CLRB Stock News - GuruFocus
Ideas Watch: Can Cellectar Biosciences Inc weather a recessionPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally - MSN
Cellectar Biosciences Charts Risky Path to Approvals - TipRanks
Quarterly Trades: Does Cellectar Biosciences Inc have a sustainable dividendJuly 2025 Macro Moves & Long-Term Growth Plans - baoquankhu1.vn
Can Cellectar Biosciences Inc weather a recessionWeekly Trading Summary & Safe Capital Growth Plans - baoquankhu1.vn
Should you sell your Cellectar Biosciences stock? - Cantech Letter
Death Cross: Is Cellectar Biosciences Inc vulnerable to short sellersMarket Rally & Capital Efficiency Focused Ideas - baoquankhu1.vn
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale - AOL.com
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2025 Earnings Call Transcript - Insider Monkey
Cellectar (CLRB) Marks Significant Achievements in 2025 - GuruFocus
Cellectar Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Cellectar (CLRB) Q4 2025 Earnings Call Transcript - The Globe and Mail
CLRB: Advanced late-stage pipeline, improved financials, and set up for major regulatory milestones in 2026 - TradingView
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates - Investing News Network
CLRB: Advanced regulatory progress, reduced losses, and extended cash runway position for key 2026 milestones - TradingView
Cellectar Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Summary: Cellectar Biosciences (CLRB) FY25 net loss narrows - AlphaStreet News
CLRB: Net loss narrowed to $21.8M in 2025, but new funding is needed beyond Q3 2026 - TradingView
CLRB: Net loss narrowed as pipeline advanced toward key regulatory and clinical milestones - TradingView
Cellectar Biosciences 2025 10-K — Net loss $8.35 EPS; no revenue reported - TradingView
Cellectar (NASDAQ: CLRB) halves 2025 loss while pushing key cancer drugs - Stock Titan
Iopofosine progress at Cellectar (NASDAQ: CLRB) with pivotal WM data and FDA path - Stock Titan
Cellectar Biosciences, Inc. Advances Iopofosine I-131 Submission for Waldenström Macroglobulinemia and Initiates Phase 1b Study of CLR 125 in Triple Negative Breast Cancer - Quiver Quantitative
Insights into Cellectar Biosciences's Upcoming Earnings - Benzinga
Cellectar Biosciences, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
Cellectar Biosciences Inc expected to post a loss of $2.02 a shareEarnings Preview - TradingView
Cellectar Biosciences (CLRB) to Release Earnings on Wednesday - Defense World
Rate Cut: Is Cellectar Biosciences Inc currently under institutional pressureJuly 2025 PreEarnings & AI Forecast Swing Trade Picks - baoquankhu1.vn
CLRB SEC FilingsCellectar Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Analyst Upgrade: Will Cellectar Biosciences Inc benefit from rising consumer demandMarket Sentiment Summary & Capital Protection Trade Alerts - baoquankhu1.vn
CLRB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Nasdaq Moves: How cyclical is Cellectar Biosciences Incs revenue streamMarket Performance Recap & High Accuracy Trade Alerts - baoquankhu1.vn
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 - Investing News Network
CLRB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cancer-drug developer Cellectar sets March 4 call on 2025 results - Stock Titan
Cellectar Biosciences Inc Azioni (CLRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):